JPMorgan and RBC Capital have both upgraded their price targets for Eli Lilly & Company (LLY) due to increased demand for the company's weight-loss drugs, Mounjaro and Zepbound. JPMorgan raised its target to $1,400 from $1,300 while maintaining an Overweight rating. Similarly, RBC Capital lifted its target to $1,500 from $1,250 with an Outperform rating.

The upgrades are backed by the performance of Mounjaro and Zepbound, further fueled by Medicare's new GLP-1 Bridge program that launched on July 1, allowing eligible patients to access Zepbound for as low as $50 a month. Currently, LLY is trading around $1,235, reflecting a rise of approximately 14% year-to-date and nearing its 52-week high of $1,249.45.

Why This Matters to Investors

This news is crucial for investors as it highlights the potential for strong revenue growth in Eli Lilly's future. With the Medicare program potentially benefiting around 20 million patients, analysts are optimistic about the drug's uptake. The company's sales projections have been reported to exceed expectations, indicating robust demand.

  • JPMorgan's new price target is $1,400, exceeding the Wall Street consensus of approximately $1,305.
  • RBC Capital’s adjusted target stands at $1,500 after noting sales projections that are 1% ahead of consensus.
  • Total Q2 sales for Lilly are projected at $20.7 billion, exceeding previous estimates by about $300 million.
  • The company's 2026 revenue forecast has been raised to between $82 billion and $85 billion.

Analyst Chris Schott attributed the expected growth to two primary drivers: the international market expansion of Mounjaro and consistent U.S. demand for Zepbound. Additionally, Eli Lilly recorded revenue of $19.8 billion in Q1 2026, signifying a year-over-year increase of 55.5%. The two drugs collectively generated approximately $12.8 billion in global sales.

Future Developments to Watch

As Eli Lilly continues to experience strong demand growth, investors should keep an eye on potential upcoming milestones, including further developments regarding the GLP-1 Bridge program and updates to their drug pipeline. Recent competitive challenges faced by smaller rivals may also enhance Lilly's market position.

This material is for informational purposes only and does not constitute financial advice.